Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 1/20 | 0.54 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.50 |
| ▸ | PYGL | P06737 | 1/20 | 0.50 |
| ▸ | PYGM | P11217 | 1/20 | 0.50 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.48 |
| ▸ | GALK1 | P51570 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | PLEC | Q15149 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274830 | 0.90 | MEN1 (0.54) | SERPINE1HPSEPYGLPYGM | |
| SCHEMBL2271524 | 0.90 | PYGM (0.56) | SERPINE1HPSEPYGLPYGMGALK1 | |
| SCHEMBL2273634 | 0.90 | SERPINE1 (0.60) | SERPINE1HPSEPYGLPYGMGALK1 | |
| SCHEMBL2274811 | 0.88 | PYGM (0.57) | SERPINE1HPSEPYGLPYGMGALK1 | |
| SCHEMBL2271588 | 0.88 | SERPINE1 (0.64) | SERPINE1HPSEPYGLPYGMGALK1 | |
| SCHEMBL2269555 | 0.86 | HPSE (0.55) | SERPINE1HPSEPYGLPYGMGALK1 | |
| SCHEMBL2292513 | 0.86 | SERPINE1 (0.62) | SERPINE1HPSEGALK1CASP6MCL1 | |
| SCHEMBL2267915 | 0.85 | SERPINE1 (0.58) | SERPINE1HPSEPRSS12 | |
| SCHEMBL2274965 | 0.85 | L3MBTL1 (0.49) | SERPINE1HPSETDP1CYP2C9CYP2C19 | |
| SCHEMBL2275201 | 0.85 | ACLY (0.67) | SERPINE1PYGLPYGMPRSS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| CN-101094829-A | Novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | SERPINE1 101/4885HPSE 1324/4885PYGL 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.